Quantification of Etoposide Hypersensitivity

A Sensitive, Functional Method for Assessing Pluripotent Stem Cell Quality

Frank J. Secreto, Xing Li, Alyson J. Smith, Elizabeth S. Bruinsma, Ester Perales-Clemente, Saji Oommen, Gresin Hawse, Sybil C.L. Hrstka, Bonnie K. Arendt, Emma B. Brandt, Dennis A Wigle, Timothy J Nelson

Research output: Contribution to journalArticle

Abstract

Human induced pluripotent stem cells (hiPSC) hold great promise in diagnostic and therapeutic applications. However, translation of hiPSC technology depends upon a means of assessing hiPSC quality that is quantitative, high-throughput, and can decipher malignant teratocarcinoma clones from normal cell lines. These attributes are lacking in current approaches such as detection of cell surface makers, RNA profiling, and/or teratoma formation assays. The latter remains the gold standard for assessing clone quality in hiPSCs, but is expensive, time-consuming, and incompatible with high-throughput platforms. Herein, we describe a novel method for determining hiPSC quality that exploits pluripotent cells’ documented hypersensitivity to the topoisomerase inhibitor etoposide (CAS No. 33419-42-0). Based on a study of 115 unique hiPSC clones, we established that a half maximal effective concentration (EC50) value of <300 nM following 24 hours of exposure to etoposide demonstrated a positive correlation with RNA profiles and colony morphology metrics associated with high quality hiPSC clones. Moreover, our etoposide sensitivity assay (ESA) detected differences associated with culture maintenance, and successfully distinguished malignant from normal pluripotent clones independent of cellular morphology. Overall, the ESA provides a simple, straightforward method to establish hiPSC quality in a quantitative and functional assay capable of being incorporated into a generalized method for establishing a quality control standard for all types of pluripotent stem cells. Stem Cells Translational Medicine 2017;6:1829–1839.

Original languageEnglish (US)
Pages (from-to)1829-1839
Number of pages11
JournalStem cells translational medicine
Volume6
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Induced Pluripotent Stem Cells
Pluripotent Stem Cells
Etoposide
Hypersensitivity
Clone Cells
Topoisomerase Inhibitors
RNA
Teratocarcinoma
Translational Medical Research
Teratoma
Quality Control
Stem Cells
Maintenance
Technology
Cell Line

Keywords

  • Etoposide
  • Functional
  • Hypersensitivity
  • Pluripotent stem cells
  • Quantification

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology

Cite this

Quantification of Etoposide Hypersensitivity : A Sensitive, Functional Method for Assessing Pluripotent Stem Cell Quality. / Secreto, Frank J.; Li, Xing; Smith, Alyson J.; Bruinsma, Elizabeth S.; Perales-Clemente, Ester; Oommen, Saji; Hawse, Gresin; Hrstka, Sybil C.L.; Arendt, Bonnie K.; Brandt, Emma B.; Wigle, Dennis A; Nelson, Timothy J.

In: Stem cells translational medicine, Vol. 6, No. 10, 01.10.2017, p. 1829-1839.

Research output: Contribution to journalArticle

Secreto, FJ, Li, X, Smith, AJ, Bruinsma, ES, Perales-Clemente, E, Oommen, S, Hawse, G, Hrstka, SCL, Arendt, BK, Brandt, EB, Wigle, DA & Nelson, TJ 2017, 'Quantification of Etoposide Hypersensitivity: A Sensitive, Functional Method for Assessing Pluripotent Stem Cell Quality', Stem cells translational medicine, vol. 6, no. 10, pp. 1829-1839. https://doi.org/10.1002/sctm.17-0116
Secreto, Frank J. ; Li, Xing ; Smith, Alyson J. ; Bruinsma, Elizabeth S. ; Perales-Clemente, Ester ; Oommen, Saji ; Hawse, Gresin ; Hrstka, Sybil C.L. ; Arendt, Bonnie K. ; Brandt, Emma B. ; Wigle, Dennis A ; Nelson, Timothy J. / Quantification of Etoposide Hypersensitivity : A Sensitive, Functional Method for Assessing Pluripotent Stem Cell Quality. In: Stem cells translational medicine. 2017 ; Vol. 6, No. 10. pp. 1829-1839.
@article{4e222d4d0e90435397d5652b70272614,
title = "Quantification of Etoposide Hypersensitivity: A Sensitive, Functional Method for Assessing Pluripotent Stem Cell Quality",
abstract = "Human induced pluripotent stem cells (hiPSC) hold great promise in diagnostic and therapeutic applications. However, translation of hiPSC technology depends upon a means of assessing hiPSC quality that is quantitative, high-throughput, and can decipher malignant teratocarcinoma clones from normal cell lines. These attributes are lacking in current approaches such as detection of cell surface makers, RNA profiling, and/or teratoma formation assays. The latter remains the gold standard for assessing clone quality in hiPSCs, but is expensive, time-consuming, and incompatible with high-throughput platforms. Herein, we describe a novel method for determining hiPSC quality that exploits pluripotent cells’ documented hypersensitivity to the topoisomerase inhibitor etoposide (CAS No. 33419-42-0). Based on a study of 115 unique hiPSC clones, we established that a half maximal effective concentration (EC50) value of <300 nM following 24 hours of exposure to etoposide demonstrated a positive correlation with RNA profiles and colony morphology metrics associated with high quality hiPSC clones. Moreover, our etoposide sensitivity assay (ESA) detected differences associated with culture maintenance, and successfully distinguished malignant from normal pluripotent clones independent of cellular morphology. Overall, the ESA provides a simple, straightforward method to establish hiPSC quality in a quantitative and functional assay capable of being incorporated into a generalized method for establishing a quality control standard for all types of pluripotent stem cells. Stem Cells Translational Medicine 2017;6:1829–1839.",
keywords = "Etoposide, Functional, Hypersensitivity, Pluripotent stem cells, Quantification",
author = "Secreto, {Frank J.} and Xing Li and Smith, {Alyson J.} and Bruinsma, {Elizabeth S.} and Ester Perales-Clemente and Saji Oommen and Gresin Hawse and Hrstka, {Sybil C.L.} and Arendt, {Bonnie K.} and Brandt, {Emma B.} and Wigle, {Dennis A} and Nelson, {Timothy J}",
year = "2017",
month = "10",
day = "1",
doi = "10.1002/sctm.17-0116",
language = "English (US)",
volume = "6",
pages = "1829--1839",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "10",

}

TY - JOUR

T1 - Quantification of Etoposide Hypersensitivity

T2 - A Sensitive, Functional Method for Assessing Pluripotent Stem Cell Quality

AU - Secreto, Frank J.

AU - Li, Xing

AU - Smith, Alyson J.

AU - Bruinsma, Elizabeth S.

AU - Perales-Clemente, Ester

AU - Oommen, Saji

AU - Hawse, Gresin

AU - Hrstka, Sybil C.L.

AU - Arendt, Bonnie K.

AU - Brandt, Emma B.

AU - Wigle, Dennis A

AU - Nelson, Timothy J

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Human induced pluripotent stem cells (hiPSC) hold great promise in diagnostic and therapeutic applications. However, translation of hiPSC technology depends upon a means of assessing hiPSC quality that is quantitative, high-throughput, and can decipher malignant teratocarcinoma clones from normal cell lines. These attributes are lacking in current approaches such as detection of cell surface makers, RNA profiling, and/or teratoma formation assays. The latter remains the gold standard for assessing clone quality in hiPSCs, but is expensive, time-consuming, and incompatible with high-throughput platforms. Herein, we describe a novel method for determining hiPSC quality that exploits pluripotent cells’ documented hypersensitivity to the topoisomerase inhibitor etoposide (CAS No. 33419-42-0). Based on a study of 115 unique hiPSC clones, we established that a half maximal effective concentration (EC50) value of <300 nM following 24 hours of exposure to etoposide demonstrated a positive correlation with RNA profiles and colony morphology metrics associated with high quality hiPSC clones. Moreover, our etoposide sensitivity assay (ESA) detected differences associated with culture maintenance, and successfully distinguished malignant from normal pluripotent clones independent of cellular morphology. Overall, the ESA provides a simple, straightforward method to establish hiPSC quality in a quantitative and functional assay capable of being incorporated into a generalized method for establishing a quality control standard for all types of pluripotent stem cells. Stem Cells Translational Medicine 2017;6:1829–1839.

AB - Human induced pluripotent stem cells (hiPSC) hold great promise in diagnostic and therapeutic applications. However, translation of hiPSC technology depends upon a means of assessing hiPSC quality that is quantitative, high-throughput, and can decipher malignant teratocarcinoma clones from normal cell lines. These attributes are lacking in current approaches such as detection of cell surface makers, RNA profiling, and/or teratoma formation assays. The latter remains the gold standard for assessing clone quality in hiPSCs, but is expensive, time-consuming, and incompatible with high-throughput platforms. Herein, we describe a novel method for determining hiPSC quality that exploits pluripotent cells’ documented hypersensitivity to the topoisomerase inhibitor etoposide (CAS No. 33419-42-0). Based on a study of 115 unique hiPSC clones, we established that a half maximal effective concentration (EC50) value of <300 nM following 24 hours of exposure to etoposide demonstrated a positive correlation with RNA profiles and colony morphology metrics associated with high quality hiPSC clones. Moreover, our etoposide sensitivity assay (ESA) detected differences associated with culture maintenance, and successfully distinguished malignant from normal pluripotent clones independent of cellular morphology. Overall, the ESA provides a simple, straightforward method to establish hiPSC quality in a quantitative and functional assay capable of being incorporated into a generalized method for establishing a quality control standard for all types of pluripotent stem cells. Stem Cells Translational Medicine 2017;6:1829–1839.

KW - Etoposide

KW - Functional

KW - Hypersensitivity

KW - Pluripotent stem cells

KW - Quantification

UR - http://www.scopus.com/inward/record.url?scp=85030264011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030264011&partnerID=8YFLogxK

U2 - 10.1002/sctm.17-0116

DO - 10.1002/sctm.17-0116

M3 - Article

VL - 6

SP - 1829

EP - 1839

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 10

ER -